Gut Microbiome and Brain Function

Recognition of gut-brain link is growing rapidly.
- Once considered revolutionary, the idea that gut microbes influence health is now mainstream.
- Current frontier: their ability to regulate cognition, mood, and behaviour.
Key term definitions
- Microbiome: entire bacterial ecosystem in the gut (≈ $1000$ species, trillions of cells, weight ≈ $1-3\ \text{pounds}$ ).
- Probiotic: live microorganisms (often delivered in foods like yogurt) intended to confer health benefit.
- Prebiotic: non-digestible carbohydrates that nourish existing gut bacteria (e.g., GOS).

Microbiome abnormalities have been implicated in:
- Autism Spectrum Disorder (ASD)
- Anxiety disorders
- Major depressive disorder (MDD) and stress-related conditions
Quote (Emeran Mayer, UCLA): “There’s been an explosion of interest in the connections between the microbiome and the brain.”

Clinical correlation: ≈ $75\%$ of individuals with ASD exhibit gastrointestinal (GI) abnormalities (digestive issues, food allergies, gluten sensitivity).
Microbiome composition in ASD differs markedly from neurotypical controls.
Key organism: Bacteroides fragilis
- Reduced abundance observed in some autistic children.
- Caltech study (Sarkis Mazmanian et al., Cell $2013$ ):
- Mouse model with ASD-like symptoms fed human-derived B. fragilis.
- Outcomes:
  - Microbiome profile shifted toward normal.
  - Behaviour improved: ↓ anxiety, ↑ social interaction, ↓ repetitive actions.
Molecular mediator: 4-ethylphenylsulfate (4EPS)
- Mice with ASD-like phenotype show > $40\times$ higher blood 4EPS.
- Direct injection of 4EPS → induction of autism-like behaviours.
- Hypothesis: shutting down microbial 4EPS production could reverse symptoms (“turn off the faucet”).

Germ-free mouse transfer
- Collins et al.: gut bacteria from anxious humans → germ-free mice.
- Result: mice displayed heightened anxiety, underscoring transmissibility of mood-related microbiota.
Prebiotic GOS Trial (Phil Burnet, Oxford; Psychopharmacology $2015$ )
- Participants: $45$ healthy volunteers.
- Intervention: $5.5\ \text{g}$ galactooligosaccharide (GOS) daily vs placebo.
- Prior mouse work: GOS ↑ Lactobacillus & Bifidobacterium, ↑ neurotransmitters including Brain-Derived Neurotrophic Factor (BDNF).
- Human outcomes:
- ↓ cortisol (primary stress hormone).
- In rapid word-flash task, GOS group oriented toward positive over negative words—pattern similar to antidepressant or anxiolytic effects.
Yogurt/Probiotic fMRI Study (Emeran Mayer, UCLA; Gastroenterology $2013$ )
- Cohort: $25$ healthy women; $12$ consumed $1$ cup probiotic yogurt BID × $4$ weeks.
- Yogurt strains: Bifidobacterium, Streptococcus, Lactococcus, Lactobacillus.
- Pre- & post-intervention brain scans during facial-emotion tasks.
- Findings: yogurt group showed blunted neural reactivity to emotional faces—interpreted as calmer emotional processing.

Neurotransmitter synthesis by microbes
- Production of serotonin, dopamine, GABA directly in gut lumen.
- Modulation of host metabolism of these neurotransmitters.
Short-chain fatty acids (SCFAs)
- Example: butyrate linked to ↓ anxiety & depression phenotypes.
Vagus nerve activation
- Some bacterial signals directly stimulate this major gut–brain conduit.
Immunomodulation
- Microbiome ↔ immune system interplay; immune cytokines influence mood/behaviour.

Human–microbe co-habitation spans millions of years.
Cryan’s hypothesis: microbes that promote host sociability enhance their own transmission (happy → social → microbial spread).

Potential to "hack" microbiome for psychiatry, paralleling pharmacologic agents (e.g., “microbial Prozac/Valium”).
Advantages envisioned:
- Greater specificity via evolved host interactions.
- Reduced side-effect burden relative to broad-spectrum drugs.
Ongoing research aims
- Identify key strains/metabolites for targeted interventions.
- Develop dietary, probiotic, or fecal-microbiota-transplant (FMT) protocols.
- Clarify dose-response, safety, and long-term colonization dynamics.

Personalised medicine
- Individual microbiomes differ; therapies may require bespoke microbial consortia.
Safety & regulation
- Live-biotherapeutic products will need stringent oversight (pathogenicity, horizontal gene transfer, etc.).
Societal impact
- Potential stigma reduction: reframing some psychiatric disorders as partly “microbial” could shift blame from patients, but also raises concerns about biological determinism.

Gut microbes are not passive passengers; they actively generate neurochemical signals, influence host neurobiology, and may shape behaviour.
Converging animal and early human data support microbial modulation as a plausible adjunct or alternative to classical psychopharmacology.
Future psychiatric practice could incorporate dietary, probiotic, and microbiome-targeted strategies alongside—or instead of—traditional drugs.